Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same author

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.

Brain : a journal of neurology·2026
Same author

Live Attenuated Measles-Mumps-Rubella and Varicella Vaccinations and Multiple Sclerosis Activity.

JAMA network open·2026
Same author

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Multiple sclerosis and related disorders·2026
Same author

Frequency of MRI abnormalities in adult-onset MOG-IgG-associated disease at disease presentation: A cohort of Latin American patients.

Multiple sclerosis and related disorders·2026
Same journal

Compartment-specific miRNA-gene expression patterns in relapsing-remitting multiple sclerosis: Clinical blood and cerebrospinal fluid validation.

Multiple sclerosis and related disorders·2026
Same journal

Neuromyelitis optica spectrum disorder: a 5-year experience in a tertiary hospital in Northern Vietnam.

Multiple sclerosis and related disorders·2026
Same journal

Cell-type-specific Mendelian randomization analysis of brain single-nucleus eQTLs and neuromyelitis optica spectrum disorder risk.

Multiple sclerosis and related disorders·2026
Same journal

Detection of Aquaporin-4 antibody in cerebrospinal fluid in neuromyelitis optica spectrum disorder.

Multiple sclerosis and related disorders·2026
Same journal

Adjunctive gypenosides for acute optic neuritis: A prematurely terminated randomized, double-blind, placebo-controlled pilot trial in a cohort with frequent AQP4-IgG positivity.

Multiple sclerosis and related disorders·2026
Same journal

Genetic and molecular architecture of multiple sclerosis in gulf cooperation council populations: A scoping review and regional precision-neurology perspective.

Multiple sclerosis and related disorders·2026
See all related articles

Related Experiment Video

Updated: Oct 3, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Rebound activity after fingolimod cessation: A case - control study.

Andres Barboza1, María Inés Gaitán2, Ricardo Alonso3

  • 1Department of Neurology, Hospital Central de Mendoza, Mendoza, Argentina.

Multiple Sclerosis and Related Disorders
|February 15, 2022
PubMed
Summary
This summary is machine-generated.

This study found no identifiable risk factors for multiple sclerosis (MS) rebound activity (RA) after stopping fingolimod. Further research is needed to understand and predict MS RA.

Keywords:
Case-control studiesFingolimodMultiple sclerosisRebound activity

More Related Videos

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.3K
Author Spotlight: Advancing Upper Limb Rehabilitation in Patients with Right Hemisphere Damage Using Assisted Active Exercise
04:43

Author Spotlight: Advancing Upper Limb Rehabilitation in Patients with Right Hemisphere Damage Using Assisted Active Exercise

Published on: February 9, 2024

1.2K

Related Experiment Videos

Last Updated: Oct 3, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.3K
Author Spotlight: Advancing Upper Limb Rehabilitation in Patients with Right Hemisphere Damage Using Assisted Active Exercise
04:43

Author Spotlight: Advancing Upper Limb Rehabilitation in Patients with Right Hemisphere Damage Using Assisted Active Exercise

Published on: February 9, 2024

1.2K

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple Sclerosis (MS) rebound activity (RA) is an increasing concern following withdrawal of disease-modifying therapies like fingolimod.
  • Predictors and frequency of MS RA remain largely unknown, necessitating investigation, especially given fingolimod's common use in Argentina.

Purpose of the Study:

  • To identify risk factors for developing RA after fingolimod cessation.
  • To characterize the clinical presentation, management, and outcomes of MS RA.

Main Methods:

  • A multicenter, retrospective, case-control study involving patients with MS who discontinued fingolimod.
  • Data collected included demographics, MS phenotype, treatment history, Expanded Disability Status Scale (EDSS) scores, and MRI findings.

Main Results:

  • 26 cases of RA were identified and matched with controls.
  • The median time to RA onset was 50 days, with 68% experiencing EDSS worsening at 3 months.
  • No significant differences in risk factors (age, gender, phenotype, EDSS, treatment history) were found between RA cases and controls.

Conclusions:

  • This study did not identify specific risk factors for predicting RA after fingolimod cessation.
  • Larger, prospective studies are required to confirm these findings and better understand MS RA.